Call for Abstracts
Abstract Submission Period:
Tuesday, October 6, 2026 - Tuesday, December 15, 2026 (Japan Standard Time, UTC+9)
Late submissions will not be accepted.Tuesday, October 6, 2026 - Tuesday, December 15, 2026 (Japan Standard Time, UTC+9)
All abstracts must be submitted in English exclusively via the online abstract submission system.
Presentation type
FujiRetina2027 will accept poster presentations only.
All presenters are required to attend the meeting in person and mount their own posters.
FujiRetina2027 welcomes submissions that have been presented at other domestic or international scientific meetings.
Several outstanding posters will be selected as candidates for the Best Poster Awards.
Nominated authors will be invited to give a short oral presentation during the meeting in addition to their poster presentation.
The Best Poster Award winners will be announced and recognized at the Gala Party on March 27, 2027.
Category
Please select one option from each section below:
Section 1: Field Type
Section 2: Specialty Category| A | Medical | B | Surgical |
|---|
Select an appropriate category from the following list.
| 01 | Basic medicine | 09 | Central serous chorioretinopathy |
|---|---|---|---|
| 02 | Diagnosis/Examination | 10 | Age-related macular degeneration |
| 03 | Retinal detachment | 11 | Retinal dystrophies |
| 04 | Diabetic retinopathy | 12 | Vitrectomy |
| 05 | Retinal vein occlusion | 13 | Treatments other than surgery |
| 06 | Pathologic myopia | 14 | Low vision |
| 07 | Macular hole/Epiretinal membrane | 15 | Other categories |
| 08 | Macular edema |
Submission Guidelines
FIRST (PRESENTING) AUTHOR
- 1.The first author will be the presenting author. The first author is expected to register, pay the full registration fee, prepare the presentation, and attend the conference.
- 2.Please provide an accurate email address of the first author.
Results and correspondence regarding the abstract will be sent to the first author by email. - 3.A first author may submit only one abstract as the presenting author.
CO-AUTHOR(S)
A maximum of 12 co-authors are allowed for each abstract.
Please enter names and affiliations exactly as they should appear in published materials.
Please enter names and affiliations exactly as they should appear in published materials.
ABSTRACT TITLE
The abstract title must not exceed 100 characters, including spaces.
CONTENTS
It is advised to include PURPOSE, METHODS, RESULTS and CONCLUSIONS.
The abstract must not exceed 250 words.
Do not include graphs, tables, images, and references in the abstract.
The abstract must not exceed 250 words.
Do not include graphs, tables, images, and references in the abstract.
Declaration of conflict of interest is mandatory for all authors (See below for details).
On the abstract submission form, please select whether you have obtained the approval of the ethics committee, e.g. IRB, or if it is not necessary. This does not need to be stated in the abstract text.
Regarding the approval of the animal research and ethics committee, e.g. IACUC, please select whether you have obtained the approval of the committee or if it was not necessary, on the abstract submission form. The author is not required to mention it in the abstract body.
On the abstract submission form, please select whether you have obtained an informed consent or if it is not necessary. This does not need to be stated in the abstract text.
Travel Grant
FujiRetina encourages non-Japanese overseas ophthalmologists to submit abstracts. Ten abstracts will be selected as travel grant recipients by the Organizing Committee. 700 USD will be awarded to the first author of the submitted abstract. When selecting the appropriate category, please also select the travel grant application at the same time.
Note
The travel grants will be presented to the grant winners after their abstract presentations at the meeting. All travel grant recipients must attend FujiRetina in person.
Travel grant recipients are responsible for making their own arrangements for transportation to the venue and accommodation during the meeting period.
FujiRetina will not provide any stipends or reimbursements beyond 700 USD.
The results of the Travel Grant selection will be announced by email in early February 2027.
Practicing physicians and trainees are all eligible for the travel grants.
Travel grant recipients are responsible for making their own arrangements for transportation to the venue and accommodation during the meeting period.
FujiRetina will not provide any stipends or reimbursements beyond 700 USD.
The results of the Travel Grant selection will be announced by email in early February 2027.
Practicing physicians and trainees are all eligible for the travel grants.
Notification of Receipt of Abstracts
For registration confirmation, notification will be sent to the registered e-mail address. If you do not receive notification at the registered e-mail address within 24 hours, please inform the secretariat. For submissions, notification of acceptance or rejection will be sent to the registered e-mail address in early February 2027 (Tentative).
If the registration fee is not paid by the deadline specified by the Secretariat, the abstract will be deemed withdrawn.
If the registration fee is not paid by the deadline specified by the Secretariat, the abstract will be deemed withdrawn.
Conflict of Interest
Authors have to report any conflict of interest at the beginning of any presentation at FujiRetina. If the presentation is accepted, the category of conflict of interest and company names must be disclosed in the poster for presentation based on “the rules for conflict of interest of Japanese Ophthalmological Society."
* In the case of "Category P" (the author holds a patent or is in the process of applying for a patent), the company name does not need to describe.
If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
A. Presentations to Which These Rules are Applicable
These rules are applicable to all presentations, including those in Co-Sponsored Seminars, Free Paper, Panel Discussion, Poster presentation, etc.B. Report on Conflict of Interest at Abstract Submission
Report on the potential conflict of interest with companies within the last three years no matter whether it's concerned with or without the content of your presentation. If conflict of interest is “present," enter the category, class and company names after each author's name in the entry field of “Conflict of Interest" on the abstract submission form. If conflict of interest is absent, enter “category N." Confirm the declaration is correct prior to the registration. Categories and classes are as follows.1. Categories
F (Financial Support):
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs.
(*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.
I (Personal Financial Interest):
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.
E (Employee):
In the case where the author is an employee of an interested company.
In the case where the author is an employee of an interested company.
C (Consultant):
In the case where the author is currently, or was within the past three years, a consultant of an interested company.
In the case where the author is currently, or was within the past three years, a consultant of an interested company.
P (Patent):
In the case where the author holds a patent or is in the process of applying for a patent.
In the case where the author holds a patent or is in the process of applying for a patent.
R:
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.
2. Class
Ⅰ．0 yen
Ⅱ．From 1 to less than 500,000 yen
Ⅲ．From 500,000 to 5,000,000 yen
Ⅳ．Over 5,000,000 yen
*Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.
Ⅱ．From 1 to less than 500,000 yen
Ⅲ．From 500,000 to 5,000,000 yen
Ⅳ．Over 5,000,000 yen
*Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.
Disclosures in the Abstract and Slide Decks
Abstract:
The presence or absence of conflict of interest to be disclosed for the author (including co-authors) will be automatically shown at the end of the abstract, according to “the detailed rules of the standard for disclosure in the Japanese Ophthalmological Society." For categories F, C and R, only class IV (over 5,000,000 yen) will be corresponded to “presence".
Slide and Poster:
If the authors have to disclose any conflict of interest, the category and company names* should be described after the authors' names in the second slide and at the end of the poster. For categories F, C and R, only class IV (over 5,000,000 yen) should be disclosed.
If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
Personal Information Protection
"Names" and "contact addresses" provided to us at registration for the meeting shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any information related to the presentation. In addition, the “presenters' names," “affiliation names," “title" and “abstract text" shall be used for publication in the program/proceedings and on the website, but not for other purposes. The registration process for applications has been commissioned to c/o JTB Communication Design, Inc. in order to facilitate management operations.
Abstract Submission
Inquiries
FujiRetina Secretariat
c/o JTB Communication Design, Inc.,
Osaka Dojimahama Tower 5F, 1-1-27 Dojimahama, Kita-ku, Osaka 530-0004, Japan
E-mail: fujiretina@jtbcom.co.jp
c/o JTB Communication Design, Inc.,
Osaka Dojimahama Tower 5F, 1-1-27 Dojimahama, Kita-ku, Osaka 530-0004, Japan
E-mail: fujiretina@jtbcom.co.jp